NASDAQ$ERAS
Erasca Inc · Q4 2023 earnings
Q4 2023 earnings · · Investor relations
Briefing
Reported business updates and financial results for the fourth quarter and full year ended December 31, 2023.
Erasca reported a net loss of $29.7 million for the quarter ended December 31, 2023, compared to a net loss of $135.3 million for the quarter ended December 31, 2022. Cash, cash equivalents, and marketable securities were $322.0 million as of December 31, 2023.
- Gained global registrational clarity for naporafenib and achieved key clinical milestones for naporafenib, ERAS-007, and ERAS-801
- Multiple data readouts expected in 2024 for naporafenib (SEACRAFT-1), ERAS-007 (HERKULES-3), and ERAS-801 (THUNDERBBOLT-1) and planned initiation of pivotal SEACRAFT-2 trial
- Robust balance sheet with cash, cash equivalents, and marketable securities of $322 million as of December 31, 2023
- Granted Fast Track Designation for Naporafenib
Headline financials
Revenue & EPS history
Erasca · Revenue · Quarterly
$5.58M
Forward guidance
Erasca expects multiple data readouts in 2024 for naporafenib (SEACRAFT-1), ERAS-007 (HERKULES-3), and ERAS-801 (THUNDERBBOLT-1) and planned initiation of pivotal SEACRAFT-2 trial
Tailwinds
- Initial Phase 1b combination data expected between the second and fourth quarters of 2024 for SEACRAFT-1
- Phase 3 trial initiation expected in the first half of 2024 for SEACRAFT-2
- Phase 1b combination data expected in the first half of 2024 for HERKULES-3
- Initial Phase 1 monotherapy data expected in 2024 for THUNDERBBOLT-1
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 17 quarterly earnings reports · overlaid with Q4 2023
+1.1%
Avg return
Earnings day
+1.0%
Avg return
5 days after
+1.3%
Avg return
30 days after
58%
11 / 19 earnings
Positive
+11.0%
Q3 2022
Best reaction
-10.1%
Q1 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +3.3% | +1.0% | +32.1% | |
| Q4 2025 | -4.3% | -7.8% | +16.1% | |
| Q3 2025 | -4.2% | +7.9% | +35.8% | |
| Q1 2025 | -4.0% | -5.8% | +9.3% | |
| Q4 2024 | +6.0% | -8.2% | +25.0% | |
| Q3 2024 | -8.4% | -14.1% | -15.4% | |
| Q2 2024 | +8.3% | +16.7% | +27.9% | |
| Q1 2024 | -10.1% | -12.8% | +8.9% | |
| Q4 2023 | +4.0% | +9.1% | -4.5% | |
| Q3 2023 | -8.6% | -1.8% | -15.0% | |
| Q2 2023 | +10.6% | -3.2% | -0.8% | |
| Q1 2023 | -1.0% | -3.8% | -5.6% | |
| Q4 2022 | -2.7% | -5.8% | -3.8% | |
| Q3 2022 | +11.0% | +20.7% | -19.1% | |
| Q2 2022 | +2.5% | +4.4% | -10.8% | |
| Q1 2022 | +2.8% | +9.4% | -4.6% | |
| Q4 2021 | +9.1% | +8.1% | -9.7% | |
| Q3 2021 | +2.2% | -3.1% | -28.9% | |
| Q2 2021 | +4.8% | +8.9% | -12.3% | |
| Q1 2021 | — | — | — | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro